Advanced LC-MS applications in bioanalysis / / editors, Long Yuan [and four others] |
Pubbl/distr/stampa | London, England : , : Future Science Ltd, , 2015 |
Descrizione fisica | 1 online resource (225 pages) : illustrations (some color) |
Disciplina | 543.0894 |
Soggetto topico |
Liquid chromatography
Mass spectrometry Drugs - Analysis |
Soggetto genere / forma | Electronic books. |
ISBN |
1-910420-02-6
1-910420-01-8 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910467797303321 |
London, England : , : Future Science Ltd, , 2015 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Advanced LC-MS applications in bioanalysis / / editors, Long Yuan [and four others] |
Pubbl/distr/stampa | London, England : , : Future Science Ltd, , 2015 |
Descrizione fisica | 1 online resource (225 pages) : illustrations (some color) |
Disciplina | 543.0894 |
Soggetto topico |
Liquid chromatography
Mass spectrometry Drugs - Analysis |
ISBN |
1-910420-02-6
1-910420-01-8 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910794851903321 |
London, England : , : Future Science Ltd, , 2015 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Advanced LC-MS applications in bioanalysis / / editors, Long Yuan [and four others] |
Pubbl/distr/stampa | London, England : , : Future Science Ltd, , 2015 |
Descrizione fisica | 1 online resource (225 pages) : illustrations (some color) |
Disciplina | 543.0894 |
Soggetto topico |
Liquid chromatography
Mass spectrometry Drugs - Analysis |
ISBN |
1-910420-02-6
1-910420-01-8 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910820796703321 |
London, England : , : Future Science Ltd, , 2015 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Advances in drug testing and drug delivery systems / / Kin Fong Lei, I-Chi Lee and Yi-Chen Li |
Autore | Lei Kin Fong |
Pubbl/distr/stampa | Hauppauge, New York : , : Nova Science Publishers, Incorporated, , [2017] |
Descrizione fisica | 1 online resource (245 pages) : illustrations (some color) |
Disciplina | 615.1/901 |
Collana | Substance abuse assessment, interventions and treatment |
Soggetto topico |
Drugs - Analysis
Drug testing Drug delivery systems |
ISBN | 1-63485-892-1 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910159435003321 |
Lei Kin Fong
![]() |
||
Hauppauge, New York : , : Nova Science Publishers, Incorporated, , [2017] | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Analysis of drug impurities [[electronic resource] /] / edited by Richard J. Smith and Michael L. Webb |
Pubbl/distr/stampa | Oxford ; ; Ames, Iowa, : Blackwell, 2007 |
Descrizione fisica | 1 online resource (290 p.) |
Disciplina |
615.1901
615/.1901 |
Altri autori (Persone) |
SmithRichard J
WebbMichael L |
Collana | Analytical chemistry series |
Soggetto topico |
Drugs - Analysis
Materia medica |
Soggetto genere / forma | Electronic books. |
ISBN |
1-281-32024-2
9786611320249 0-470-98874-6 0-470-99422-3 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Analysis of Drug Impurities; Contents; Preface; List of contributors; 1 Organic impurities in drug substance: origin, control, and measurement; 1.1 Introduction; 1.2 Origin of impurities; 1.2.1 Process impurities; 1.2.2 Degradation impurities; 1.2.3 Contamination impurities; 1.2.4 Other impurities; 1.3 Control of drug substance impurities; 1.3.1 Control of residual solvents; 1.3.2 Control of synthetic impurities; 1.3.3 Control of impurities in biological and botanical products; 1.3.4 Purification processes; 1.3.5 Control of impurities from packaging; 1.3.6 Control of contamination impurities
1.3.7 Control of degradants on stability1.4 Measurement of drug substance impurities; 1.4.1 HPLC; 1.4.2 GC; 1.4.3 CE; 1.4.4 General considerations; 1.5 Conclusions; Disclaimer; References; 2 Organic impurities in drug products: origin, control and measurement; 2.1 Introduction; 2.2 Analytical methodology; 2.3 Drug-excipient compatibility experimental design; 2.4 Degradation mechanisms; 2.5 Excipients' role in drug product destabilisation; 2.6 Processing as a source of moisture; 2.7 Hydrolysis; 2.8 Oxidation; 2.9 Photolysis; 2.10 Impact of processing on photostability 2.11 Miscellaneous reactions2.12 Container-closure systems; References; 3 Stereochemical impurities; 3.1 Introduction; 3.2 Separation techniques: direct resolution; 3.2.1 HPLC using CSPs; 3.2.2 HPLC using chiral mobile-phase additives; 3.2.3 Capillary electrophoresis using chiral selectors; 3.2.4 Supercritical fluid chromatography using chiral stationary phases; 3.2.5 Gas chromatography using chiral stationary phases; 3.3 Separation techniques: indirect resolution; 3.4 Non-separation techniques; 3.4.1 Chiroptical spectroscopy; 3.4.2 Nuclear magnetic resonance spectroscopy; 3.5 Conclusions AcknowledgementsReferences; 4 Low-level measurement of potent toxins; 4.1 Introduction; 4.2 Classes of genotoxic impurity; 4.2.1 Alkylating agents; 4.2.2 Reactive amines; 4.2.3 Fused tricyclics; 4.2.4 Substituted purines and pyrimidines; 4.2.5 Hydroperoxides; 4.3 The analytical challenge of genetic; 4.4 Gas chromatography; 4.4.1 Sample introduction techniques; 4.4.2 Detectors; 4.5 High-performance liquid chromatography; 4.5.1 Separation modes; 4.5.2 Detection techniques; 4.6 Supercritical fluid chromatography; 4.7 Thin-layer chromatography; 4.8 Sample pre-concentration 4.8.1 Liquid-liquid extraction4.8.2 Solid-phase extraction; 4.8.3 Solid-phase microextraction; 4.8.4 Liquid-phase microextraction; 4.9 Other techniques; 4.9.1 Electrochemical measurements; 4.9.2 Derivatisation methods; 4.10 Adapting analytical methods from fields beyond pharmaceuticalsimpurities analysis; 4.10.1 Antineoplastic agents; 4.10.2 Other fields; 4.11 Validation of trace analytical methods; 4.11.1 Sensitivity; 4.11.2 Specificity; 4.11.3 Accuracy; 4.11.4 Solution stability; 4.11.5 Linearity and precision; 4.12 Conclusions; References; 5 A systematic approach to impurity identification 5.1 Introduction |
Record Nr. | UNINA-9910145261903321 |
Oxford ; ; Ames, Iowa, : Blackwell, 2007 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Analysis of drug impurities [[electronic resource] /] / edited by Richard J. Smith and Michael L. Webb |
Pubbl/distr/stampa | Oxford ; ; Ames, Iowa, : Blackwell, 2007 |
Descrizione fisica | 1 online resource (290 p.) |
Disciplina |
615.1901
615/.1901 |
Altri autori (Persone) |
SmithRichard J
WebbMichael L |
Collana | Analytical chemistry series |
Soggetto topico |
Drugs - Analysis
Materia medica |
ISBN |
1-281-32024-2
9786611320249 0-470-98874-6 0-470-99422-3 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Analysis of Drug Impurities; Contents; Preface; List of contributors; 1 Organic impurities in drug substance: origin, control, and measurement; 1.1 Introduction; 1.2 Origin of impurities; 1.2.1 Process impurities; 1.2.2 Degradation impurities; 1.2.3 Contamination impurities; 1.2.4 Other impurities; 1.3 Control of drug substance impurities; 1.3.1 Control of residual solvents; 1.3.2 Control of synthetic impurities; 1.3.3 Control of impurities in biological and botanical products; 1.3.4 Purification processes; 1.3.5 Control of impurities from packaging; 1.3.6 Control of contamination impurities
1.3.7 Control of degradants on stability1.4 Measurement of drug substance impurities; 1.4.1 HPLC; 1.4.2 GC; 1.4.3 CE; 1.4.4 General considerations; 1.5 Conclusions; Disclaimer; References; 2 Organic impurities in drug products: origin, control and measurement; 2.1 Introduction; 2.2 Analytical methodology; 2.3 Drug-excipient compatibility experimental design; 2.4 Degradation mechanisms; 2.5 Excipients' role in drug product destabilisation; 2.6 Processing as a source of moisture; 2.7 Hydrolysis; 2.8 Oxidation; 2.9 Photolysis; 2.10 Impact of processing on photostability 2.11 Miscellaneous reactions2.12 Container-closure systems; References; 3 Stereochemical impurities; 3.1 Introduction; 3.2 Separation techniques: direct resolution; 3.2.1 HPLC using CSPs; 3.2.2 HPLC using chiral mobile-phase additives; 3.2.3 Capillary electrophoresis using chiral selectors; 3.2.4 Supercritical fluid chromatography using chiral stationary phases; 3.2.5 Gas chromatography using chiral stationary phases; 3.3 Separation techniques: indirect resolution; 3.4 Non-separation techniques; 3.4.1 Chiroptical spectroscopy; 3.4.2 Nuclear magnetic resonance spectroscopy; 3.5 Conclusions AcknowledgementsReferences; 4 Low-level measurement of potent toxins; 4.1 Introduction; 4.2 Classes of genotoxic impurity; 4.2.1 Alkylating agents; 4.2.2 Reactive amines; 4.2.3 Fused tricyclics; 4.2.4 Substituted purines and pyrimidines; 4.2.5 Hydroperoxides; 4.3 The analytical challenge of genetic; 4.4 Gas chromatography; 4.4.1 Sample introduction techniques; 4.4.2 Detectors; 4.5 High-performance liquid chromatography; 4.5.1 Separation modes; 4.5.2 Detection techniques; 4.6 Supercritical fluid chromatography; 4.7 Thin-layer chromatography; 4.8 Sample pre-concentration 4.8.1 Liquid-liquid extraction4.8.2 Solid-phase extraction; 4.8.3 Solid-phase microextraction; 4.8.4 Liquid-phase microextraction; 4.9 Other techniques; 4.9.1 Electrochemical measurements; 4.9.2 Derivatisation methods; 4.10 Adapting analytical methods from fields beyond pharmaceuticalsimpurities analysis; 4.10.1 Antineoplastic agents; 4.10.2 Other fields; 4.11 Validation of trace analytical methods; 4.11.1 Sensitivity; 4.11.2 Specificity; 4.11.3 Accuracy; 4.11.4 Solution stability; 4.11.5 Linearity and precision; 4.12 Conclusions; References; 5 A systematic approach to impurity identification 5.1 Introduction |
Record Nr. | UNISA-996218619503316 |
Oxford ; ; Ames, Iowa, : Blackwell, 2007 | ||
![]() | ||
Lo trovi qui: Univ. di Salerno | ||
|
Analysis of drug impurities [[electronic resource] /] / edited by Richard J. Smith and Michael L. Webb |
Pubbl/distr/stampa | Oxford ; ; Ames, Iowa, : Blackwell, 2007 |
Descrizione fisica | 1 online resource (290 p.) |
Disciplina |
615.1901
615/.1901 |
Altri autori (Persone) |
SmithRichard J
WebbMichael L |
Collana | Analytical chemistry series |
Soggetto topico |
Drugs - Analysis
Materia medica |
ISBN |
1-281-32024-2
9786611320249 0-470-98874-6 0-470-99422-3 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Analysis of Drug Impurities; Contents; Preface; List of contributors; 1 Organic impurities in drug substance: origin, control, and measurement; 1.1 Introduction; 1.2 Origin of impurities; 1.2.1 Process impurities; 1.2.2 Degradation impurities; 1.2.3 Contamination impurities; 1.2.4 Other impurities; 1.3 Control of drug substance impurities; 1.3.1 Control of residual solvents; 1.3.2 Control of synthetic impurities; 1.3.3 Control of impurities in biological and botanical products; 1.3.4 Purification processes; 1.3.5 Control of impurities from packaging; 1.3.6 Control of contamination impurities
1.3.7 Control of degradants on stability1.4 Measurement of drug substance impurities; 1.4.1 HPLC; 1.4.2 GC; 1.4.3 CE; 1.4.4 General considerations; 1.5 Conclusions; Disclaimer; References; 2 Organic impurities in drug products: origin, control and measurement; 2.1 Introduction; 2.2 Analytical methodology; 2.3 Drug-excipient compatibility experimental design; 2.4 Degradation mechanisms; 2.5 Excipients' role in drug product destabilisation; 2.6 Processing as a source of moisture; 2.7 Hydrolysis; 2.8 Oxidation; 2.9 Photolysis; 2.10 Impact of processing on photostability 2.11 Miscellaneous reactions2.12 Container-closure systems; References; 3 Stereochemical impurities; 3.1 Introduction; 3.2 Separation techniques: direct resolution; 3.2.1 HPLC using CSPs; 3.2.2 HPLC using chiral mobile-phase additives; 3.2.3 Capillary electrophoresis using chiral selectors; 3.2.4 Supercritical fluid chromatography using chiral stationary phases; 3.2.5 Gas chromatography using chiral stationary phases; 3.3 Separation techniques: indirect resolution; 3.4 Non-separation techniques; 3.4.1 Chiroptical spectroscopy; 3.4.2 Nuclear magnetic resonance spectroscopy; 3.5 Conclusions AcknowledgementsReferences; 4 Low-level measurement of potent toxins; 4.1 Introduction; 4.2 Classes of genotoxic impurity; 4.2.1 Alkylating agents; 4.2.2 Reactive amines; 4.2.3 Fused tricyclics; 4.2.4 Substituted purines and pyrimidines; 4.2.5 Hydroperoxides; 4.3 The analytical challenge of genetic; 4.4 Gas chromatography; 4.4.1 Sample introduction techniques; 4.4.2 Detectors; 4.5 High-performance liquid chromatography; 4.5.1 Separation modes; 4.5.2 Detection techniques; 4.6 Supercritical fluid chromatography; 4.7 Thin-layer chromatography; 4.8 Sample pre-concentration 4.8.1 Liquid-liquid extraction4.8.2 Solid-phase extraction; 4.8.3 Solid-phase microextraction; 4.8.4 Liquid-phase microextraction; 4.9 Other techniques; 4.9.1 Electrochemical measurements; 4.9.2 Derivatisation methods; 4.10 Adapting analytical methods from fields beyond pharmaceuticalsimpurities analysis; 4.10.1 Antineoplastic agents; 4.10.2 Other fields; 4.11 Validation of trace analytical methods; 4.11.1 Sensitivity; 4.11.2 Specificity; 4.11.3 Accuracy; 4.11.4 Solution stability; 4.11.5 Linearity and precision; 4.12 Conclusions; References; 5 A systematic approach to impurity identification 5.1 Introduction |
Record Nr. | UNINA-9910830641003321 |
Oxford ; ; Ames, Iowa, : Blackwell, 2007 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Analysis of drug impurities [[electronic resource] /] / edited by Richard J. Smith and Michael L. Webb |
Pubbl/distr/stampa | Oxford ; ; Ames, Iowa, : Blackwell, 2007 |
Descrizione fisica | 1 online resource (290 p.) |
Disciplina |
615.1901
615/.1901 |
Altri autori (Persone) |
SmithRichard J
WebbMichael L |
Collana | Analytical chemistry series |
Soggetto topico |
Drugs - Analysis
Materia medica |
ISBN |
1-281-32024-2
9786611320249 0-470-98874-6 0-470-99422-3 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Analysis of Drug Impurities; Contents; Preface; List of contributors; 1 Organic impurities in drug substance: origin, control, and measurement; 1.1 Introduction; 1.2 Origin of impurities; 1.2.1 Process impurities; 1.2.2 Degradation impurities; 1.2.3 Contamination impurities; 1.2.4 Other impurities; 1.3 Control of drug substance impurities; 1.3.1 Control of residual solvents; 1.3.2 Control of synthetic impurities; 1.3.3 Control of impurities in biological and botanical products; 1.3.4 Purification processes; 1.3.5 Control of impurities from packaging; 1.3.6 Control of contamination impurities
1.3.7 Control of degradants on stability1.4 Measurement of drug substance impurities; 1.4.1 HPLC; 1.4.2 GC; 1.4.3 CE; 1.4.4 General considerations; 1.5 Conclusions; Disclaimer; References; 2 Organic impurities in drug products: origin, control and measurement; 2.1 Introduction; 2.2 Analytical methodology; 2.3 Drug-excipient compatibility experimental design; 2.4 Degradation mechanisms; 2.5 Excipients' role in drug product destabilisation; 2.6 Processing as a source of moisture; 2.7 Hydrolysis; 2.8 Oxidation; 2.9 Photolysis; 2.10 Impact of processing on photostability 2.11 Miscellaneous reactions2.12 Container-closure systems; References; 3 Stereochemical impurities; 3.1 Introduction; 3.2 Separation techniques: direct resolution; 3.2.1 HPLC using CSPs; 3.2.2 HPLC using chiral mobile-phase additives; 3.2.3 Capillary electrophoresis using chiral selectors; 3.2.4 Supercritical fluid chromatography using chiral stationary phases; 3.2.5 Gas chromatography using chiral stationary phases; 3.3 Separation techniques: indirect resolution; 3.4 Non-separation techniques; 3.4.1 Chiroptical spectroscopy; 3.4.2 Nuclear magnetic resonance spectroscopy; 3.5 Conclusions AcknowledgementsReferences; 4 Low-level measurement of potent toxins; 4.1 Introduction; 4.2 Classes of genotoxic impurity; 4.2.1 Alkylating agents; 4.2.2 Reactive amines; 4.2.3 Fused tricyclics; 4.2.4 Substituted purines and pyrimidines; 4.2.5 Hydroperoxides; 4.3 The analytical challenge of genetic; 4.4 Gas chromatography; 4.4.1 Sample introduction techniques; 4.4.2 Detectors; 4.5 High-performance liquid chromatography; 4.5.1 Separation modes; 4.5.2 Detection techniques; 4.6 Supercritical fluid chromatography; 4.7 Thin-layer chromatography; 4.8 Sample pre-concentration 4.8.1 Liquid-liquid extraction4.8.2 Solid-phase extraction; 4.8.3 Solid-phase microextraction; 4.8.4 Liquid-phase microextraction; 4.9 Other techniques; 4.9.1 Electrochemical measurements; 4.9.2 Derivatisation methods; 4.10 Adapting analytical methods from fields beyond pharmaceuticalsimpurities analysis; 4.10.1 Antineoplastic agents; 4.10.2 Other fields; 4.11 Validation of trace analytical methods; 4.11.1 Sensitivity; 4.11.2 Specificity; 4.11.3 Accuracy; 4.11.4 Solution stability; 4.11.5 Linearity and precision; 4.12 Conclusions; References; 5 A systematic approach to impurity identification 5.1 Introduction |
Record Nr. | UNINA-9910840949003321 |
Oxford ; ; Ames, Iowa, : Blackwell, 2007 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Analytical methods for therapeutic drug monitoring and toxicology [[electronic resource] /] / Q. Alan Xu, Timothy L. Madden |
Autore | Xu Quanyun A. <1961-> |
Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2011 |
Descrizione fisica | 1 online resource (518 p.) |
Disciplina | 615/.19 |
Altri autori (Persone) | MaddenTimothy L |
Soggetto topico |
Drugs - Analysis
Drugs - Toxicity testing |
ISBN |
0-470-92279-6
1-282-90480-9 9786612904806 0-470-90978-1 0-470-90979-X |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
ANALYTICAL METHODS FOR THERAPEUTIC DRUGMONITORING AND TOXICOLOGY; CONTENTS; Preface; MONOGRAPHS; Abacavir; Abecarnil; Acamprosate Calcium; Acebutolol Hydrochloride; Aceclofenac; Acemetacin; Acenocoumarol; Acetaminophen; Acetazolamide; Aconitine; Acrivastine; Acyclovir; Albendazole; Albuterol; Alcuronium Chloride; Alfentanil Hydrochloride; Alfuzosin Hydrochloride; Allobarbital; Allopurinol; Alprazolam; Alprenolol; Ambroxol Hydrochloride; Amikacin; Amiloride Hydrochloride; Amiodarone Hydrochloride; Amisulpride; Amitriptyline Hydrochloride; Amlodipine Besylate; Amobarbital; Amoxapine
AmoxicillinAmphetamine; Amphotericin B; Ampicillin; Amprenavir; Amsacrine; Apomorphine Hydrochloride; Aripiprazole; Arotinolol Hydrochloride; Artemisinin; Artesunate; Aspirin; Atazanavir Sulfate; Atenolol; Azathioprine; Azithromycin; Baclofen; Barbital; Benactyzine Hydrochloride; Bendroflumethiazide; Benzthiazide; Benzylpenicillin Potassium; Betaxolol Hydrochloride; Biapenem; Bisoprolol Fumarate; Bromazepam; Bromisoval; Bromperidol; Brompheniramine Maleate; Buflomedil Hydrochloride; Bumetanide; Buparvaquone; Bupivacaine Hydrochloride; Buprenorphine; Bupropion Hydrochloride Buspirone HydrochlorideBusulfan; Caffeine; Candesartan Cilexetil; Canrenone; Capecitabine; Capreomycin Sulfate; Carbamazepine; Carbidopa; Carbinoxamine Maleate; Carboplatin; Carbromal; Carteolol Hydrochloride; Carvedilol; Caspofungin Acetate; Cathine; Cefaclor; Cefadroxil; Cefalexin; Cefazolin Sodium; Cefdinir; Cefditoren Pivoxil; Cefepime Hydrochloride; Cefixime; Cefotaxime Sodium; Cefozopran Hydrochloride; Cefpiramide; Cefpirome Sulfate; Cefpodoxime Proxetil; Cefprozil; Ceftazidime; Ceftibuten; Ceftiofur Hydrochloride; Ceftizoxime Sodium; Ceftriaxone Sodium; Cefuroxime; Celecoxib Celiprolol HydrochlorideCephalexin Hydrochloride; Cetirizine Hydrochloride; Chloramphenicol; Chlordiazepoxide; Chlorhexidine Acetate; Chlorothiazide; Chlorphenamine Maleate; Chlorpromazine; Chlorpropamide; Chlorthalidone; Cilnidipine; Cimetidine; Ciprofloxacin; Cisapride; Cisplatin; Citalopram Hydrobromide; Clarithromycin; Clavulanate Potassium; Clemastine Fumarate; Clenbuterol Hydrochloride; Clinafloxacin Hydrochloride; Clobazam; Clofazimine; Clomipramine Hydrochloride; Clonazepam; Clonidine; Clopamide; Cloperastine; Clotiapine; Cloxacillin; Clozapine; Cocaine; Codeine; Cotinine CyclopenthiazideCyclophosphamide; Cyclosporine; Cyproheptadine Hydrochloride; Cytarabine; Dabigatran Etexilate; Dapsone; Daptomycin; Darunavir; Debrisoquine Sulfate; Decitabine; Delavirdine Mesylate; Derxazoxane; Desipramine Hydrochloride; Desloratadine; Dexamethasone; Dexfenfluramine Hydrochloride; Dextromethorphan Hydrobromide; Dextromoramide Tartrate; Diamorphine Hydrochloride; Diazepam; Dibenzepin Hydrochloride; Diclofenac Sodium; Diclofenamide; Dicloxacillin Sodium; Didanosine; Digoxin; Diltiazem Hydrochloride; Dimethylformamide; Dimethylsulfoxide; Diphemanil Metilsulfate Diphenhydramine Hydrochloride |
Record Nr. | UNINA-9910133588903321 |
Xu Quanyun A. <1961->
![]() |
||
Hoboken, N.J., : Wiley, c2011 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Applications of high-resolution mass spectrometry in drug discovery and development / / editor, Lekha Sleno |
Pubbl/distr/stampa | London, England : , : Future Science Ltd, , 2014 |
Descrizione fisica | 1 online resource (174 pages) : illustrations (some color), graphs |
Disciplina | 615.1901 |
Collana | Future Science |
Soggetto topico |
Drugs - Analysis
Drug development Mass spectrometry |
Soggetto genere / forma | Electronic books. |
ISBN |
1-909453-54-4
1-909453-55-2 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910464751403321 |
London, England : , : Future Science Ltd, , 2014 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|